BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23803930)

  • 1. Mucolytic agents for COPD and chronic bronchitis.
    Molle E
    Am J Nurs; 2013 Jul; 113(7):23. PubMed ID: 23803930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease: A Cochrane review summary.
    Murray AS
    Int J Nurs Stud; 2021 Dec; 124():103711. PubMed ID: 32732157
    [No Abstract]   [Full Text] [Related]  

  • 3. [Qualitatively reliable study proves: in chronic bronchitis or COPD--standardized Myrtol].
    MMW Fortschr Med; 2004 May; 146(19):56-7. PubMed ID: 15357482
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents.
    Poole PJ; Black PN
    Am J Respir Med; 2003; 2(5):367-70. PubMed ID: 14719989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
    Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
    Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdosteine for COPD exacerbations.
    Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses.
    Papi A; Alfano F; Bigoni T; Mancini L; Mawass A; Baraldi F; Aljama C; Contoli M; Miravitlles M
    Arch Bronconeumol; 2024 May; 60(5):269-278. PubMed ID: 38555190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
    Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
    Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis.
    Lee JS; Park DA; Hong Y; Jo KW; Lee SW; Huh JW; Oh YM; Lee SD
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):153-62. PubMed ID: 23317949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
    Cazzola M; Floriani I; Page CP
    Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD).
    Davies L; Calverley PM
    Br Med Bull; 2010; 93():217-27. PubMed ID: 20031934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic obstructive pulmonary disease exacerbation. Do we use all possibilities of outpatient therapy?].
    Leshchenko IV
    Ter Arkh; 2013; 85(10):83-7. PubMed ID: 24437224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM; Beier J; Candler H; Wittig T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2877-2884. PubMed ID: 27920515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use and misuse of antibacterial agents in chronic bronchitis].
    Brubakk O; Walstad RA
    Tidsskr Nor Laegeforen; 2003 May; 123(10):1355-6. PubMed ID: 12806677
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of mucolytic agents and macrolides in the treatment of COPD].
    Yamaya M
    Nihon Rinsho; 2016 May; 74(5):833-8. PubMed ID: 27254955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mucolytic therapy on respiratory mechanics in patients with chronic obstructive pulmonary disease.
    Schreiber J; Bohnsteen B; Rosahl W
    Eur J Med Res; 2002 Mar; 7(3):98-102. PubMed ID: 11953279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.
    Blasi F; Page C; Rossolini GM; Pallecchi L; Matera MG; Rogliani P; Cazzola M
    Respir Med; 2016 Aug; 117():190-7. PubMed ID: 27492531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease.
    Solèr M; Mütterlein R; Cozma G;
    Respiration; 2007; 74(1):26-32. PubMed ID: 16772707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
    Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
    Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.